Back to today’s briefing

Story perspectives

New Drug Reduces Cancer Progression Risk by 37%

10/8/2025

42 3

Summary

UCL Discovers Niraparib Benefits

The AMPLITUDE trial, led by University College London (UCL), found that adding niraparib to standard hormone therapy reduced progression risk by 37% in 696 men with HRR gene mutations.
Among BRCA1/BRCA2 mutation carriers, risk reduction reached 48%.
Niraparib is a PARP inhibitor that disrupts cancer DNA repair.
The results support genomic testing to identify patients who could benefit.

Summary

ASPIRE Trial Advances

The ASPIRE trial, a Phase III study by the Alliance for Clinical Trials in Oncology, tests adding docetaxel to hormone therapy for metastatic castrate-sensitive prostate cancer (mCSPC).
Enrollment includes about 1,200 participants.
Genomic profiling of TP53, PTEN, and RB1 will identify patients most likely to benefit.
Secondary endpoints include progression-free survival and quality of life; follow-up extends to a decade.

1 of 2

UCL Discovers Niraparib Benefits

The AMPLITUDE trial, led by University College London (UCL), found that adding niraparib to standard hormone therapy reduced progression risk by 37% in 696 men with HRR gene mutations.
Among BRCA1/BRCA2 mutation carriers, risk reduction reached 48%.
Niraparib is a PARP inhibitor that disrupts cancer DNA repair.
The results support genomic testing to identify patients who could benefit.

1 / 2